MARKET

BMRN

BMRN

Biomarin Pharmaceutical Inc
NASDAQ
103.02
+2.04
+2.02%
After Hours: 103.02 0 0.00% 16:57 12/01 EST
OPEN
100.71
PREV CLOSE
100.98
HIGH
103.06
LOW
99.29
VOLUME
2.01M
TURNOVER
0
52 WEEK HIGH
103.06
52 WEEK LOW
70.73
MARKET CAP
19.15B
P/E (TTM)
260.94
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 16h ago
Expert Ratings for Biomarin Pharmaceutical
Benzinga · 2d ago
Jefferies Maintains Buy on Biomarin Pharmaceutical, Raises Price Target to $120
Benzinga · 2d ago
Jefferies Adjusts BioMarin Pharmaceutical's Price Target to $120 From $100, Keeps Buy Rating
Jefferies Adjusts BioMarin Pharmaceutical's Price Target to $120 From $100, Keeps Buy Rating
MT Newswires · 2d ago
Biotech Stock BioMarin Scores Breakout After FDA Announcement
BioMarin broke out after the FDA said it wouldn't hold an advisory committee meeting on its hemophilia A gene therapy.
Investor's Business Daily · 6d ago
Why Is BioMarin (BMRN) Up 14.1% Since Last Earnings Report?
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 6d ago
Canceled AdCom, UniQure's Hemgenix Approval Show Positive Signs For BioMarin's Hemophilia Candidate
Benzinga · 11/23 18:40
Sector Update: Health Care Stocks Advancing Wednesday Afternoon
Sector Update: Health Care Stocks Advancing Wednesday Afternoon
MT Newswires · 11/23 16:05
More
About BMRN
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin 's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa) and Voxzogo (vosoritide). BioMarin's clinical development programs include Valoctocogene roxaparvovec is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A; BMN 307 is an AAV5 mediated gene therapy that is designed to normalize blood Phe concentration levels in patients with Phenylketonuria (PKU), and BMN 255 is a small-molecule therapy that is designed to treat primary hyperoxaluria type 1, a subset of chronic renal disease.

Webull offers kinds of Biomarin Pharmaceutical Inc stock information, including NASDAQ:BMRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMRN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BMRN stock methods without spending real money on the virtual paper trading platform.